Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.
about
The impact of genome-wide association studies on the pathophysiology and therapy of cardiovascular diseaseThe Promise and Challenge of Therapeutic MicroRNA Silencing in Diabetes and Metabolic DiseasesHypertriglyceridemia and Cardiovascular Diseases: RevisitedThe year in cardiology 2015: preventionNew Era of Lipid-Lowering DrugsThe emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolismWhy Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?Integrated Safety Assessment of 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human VolunteersThe Role of Emerging Risk Factors in Cardiovascular OutcomesThe Effects of 2'-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials.Very-Low-Density Lipoprotein-Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III.Genetics of coronary artery disease: discovery, biology and clinical translation.The Association of Human Apolipoprotein C-III Sialylation Proteoforms with Plasma TriglyceridesmicroRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the BrainAntisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humansReduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial resultsStabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver.Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications: A joint position statement issued by eight medical societies. 2016 update.Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease.Effect of Leptin Administration on Circulating Apolipoprotein CIII levels in Patients With LipodystrophyMetabolic Characterization of a Rare Genetic Variation Within APOC3 and Its Lipoprotein Lipase-Independent Effects.An APOC3 3'UTR variant associated with plasma triglycerides levels and coronary heart disease by creating a functional miR-4271 binding site.A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.Gene-targeting pharmaceuticals for single-gene disorders.Pleiotropic effects of apolipoprotein C3 on HDL functionality and adipose tissue metabolic activity.Mendelian Randomization Analyses for Selection of Therapeutic Targets for Cardiovascular Disease Prevention: a Note of Circumspection.Experimental Biology for the Identification of Causal Pathways in Atherosclerosis.Cardiovascular Gene Therapy: Past, Present, and Future.The Genetic Architecture of Coronary Artery Disease: Current Knowledge and Future Opportunities.Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine?Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism.Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk.Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia.Targeting ApoC-III to Reduce Coronary Disease Risk.Triglyceride Treatment in the Age of Cholesterol Reduction.Silencing of Foxp3 enhances the antitumor efficacy of GM-CSF genetically modified tumor cell vaccine against B16 melanoma.Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases.Lomitapide for the treatment of hypertriglyceridemia.Hypertriglyceridaemia and risk of coronary artery disease.PPAR-α agonists are still on the rise: an update on clinical and experimental findings.
P2860
Q26748869-E36B56E9-6AF6-4047-8532-F42264D2B4D1Q26750496-AA0B7FED-A539-4623-98D1-7C858F88BE7FQ26750954-1A98B367-AC07-4C6F-A250-18E45B06E7F8Q28072221-4999D70A-FD33-46FA-BCBB-332E4229BAF7Q28072298-944C86C2-7AD8-4A8D-8C8D-81ACB66C92CEQ28072835-B4C8B5E8-C94B-4A98-9C08-67996677FE3CQ28077776-8FF62449-C6C6-49DA-976C-A66242D28518Q28821280-7A05A467-500B-4853-BC70-D61F5A57DD1CQ30234550-2D0E0EF0-9D39-427B-AB01-378248DBE645Q33438876-4E1AA604-4E8F-4FD2-A458-E45FA382DA81Q34551430-FEA053A7-418D-41B6-B789-782B7D1E12A7Q34553141-4C1DD3CD-55B4-4206-B40F-0EEA1CB620F0Q35860314-029AC61D-3CAD-4FFB-A7F8-21D33FCBAC17Q36254032-1AEB6C0C-1876-46A9-9034-A691705E6DD1Q36617508-42D8677D-533F-4922-A61C-A2C6E0C09639Q36731776-CF27CA03-1FC2-4D89-9BB5-F6CAF9E4891CQ36775577-1B728C0B-1361-4A5D-83C3-B8003631ED0AQ36820247-065D1BDB-14C4-4018-AB2B-2727C79DD44CQ36851336-ADE0C054-66A4-4CFA-BDC5-5E9BFA28A731Q36935534-7DC80A4C-3C17-46BE-AC32-D083F80F0FE3Q37036336-FA6196A4-F19A-487E-B5DF-5A7D9250BBE6Q37254242-3958F0EA-F8A1-4EE2-9592-DEE919BC9679Q38616263-3EE3F430-D4AC-415A-A92B-F293EFA2ECF3Q38656342-956B8F90-D989-4128-8C45-C36B49E5096BQ38682093-DD35BDE5-CD51-4212-82F4-A6AED15AA9ACQ38707328-1A2DF8BD-A8B9-4CFB-87B5-FA4B4F00A103Q38723704-F2312862-3D17-42C3-BBE6-F06BD5472B0FQ38733395-B7D53187-E58E-41BE-BDCD-F2BCDD1F7DE5Q38764871-C5373AF9-373F-4936-81DF-42DE2542696FQ38780996-F89CBA33-72DD-42EA-A880-A7180BC102A2Q38839105-BB1250B7-8242-4F84-979A-AA0722C8FFA8Q38842531-8BF29EC6-845B-41BC-AC82-0BC9FDC86432Q38850010-99395600-78C6-439F-AAC5-E18C70A40203Q38904497-67A9FBD8-CEC5-43AA-BC59-C2EC28ADDEDDQ38932760-56E92E95-FCF6-4CCC-827C-60B4232152C0Q38972636-49227BF4-DF3A-4E84-8E11-083F5E544E31Q38988355-80405C73-6723-4F65-BCF1-A4A77C4C4071Q38992251-EAA3889A-6FB8-4990-9A1B-F907FCFD342CQ39181612-3FF1615C-EF43-471D-A286-FE7AB44AE59AQ39200940-5486D8EE-BCF6-4AC7-96FE-64CE3FF05B33
P2860
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.
@en
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.
@nl
type
label
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.
@en
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.
@nl
prefLabel
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.
@en
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.
@nl
P2093
P356
P1476
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.
@en
P2093
Brenda F Baker
Daniel Gaudet
Diane Brisson
John D Brunzell
John J P Kastelein
Karine Tremblay
Mark J Graham
Nicholas J Viney
Richard S Geary
Rosanne M Crooke
P304
P356
10.1056/NEJMOA1400283
P407
P577
2015-07-01T00:00:00Z